CA2054602A1 - Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system - Google Patents

Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Info

Publication number
CA2054602A1
CA2054602A1 CA002054602A CA2054602A CA2054602A1 CA 2054602 A1 CA2054602 A1 CA 2054602A1 CA 002054602 A CA002054602 A CA 002054602A CA 2054602 A CA2054602 A CA 2054602A CA 2054602 A1 CA2054602 A1 CA 2054602A1
Authority
CA
Canada
Prior art keywords
phosphorylated ligand
domain
phosphorylated
subdomain
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002054602A
Other languages
French (fr)
Other versions
CA2054602C (en
Inventor
Anthony Pawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Anthony Pawson
Mount Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthony Pawson, Mount Sinai Hospital filed Critical Anthony Pawson
Priority to US07/786,057 priority Critical patent/US5352660A/en
Priority to CA002054602A priority patent/CA2054602C/en
Priority to CA002417838A priority patent/CA2417838A1/en
Publication of CA2054602A1 publication Critical patent/CA2054602A1/en
Application granted granted Critical
Publication of CA2054602C publication Critical patent/CA2054602C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Abstract

A method for assaying a medium for the presence of a substance that affects an SH2-phosphorylated ligand regulatory system. The method employs an SH2-like domain or a subdomain thereof and a phosphorylated ligand. The phosphophorylated ligand is capable of interacting with the SH2-like domain or a subdomain thereof to form an SH2-phosphorylated ligand complex. The SH2-like domain or subdomain and/or the phosphorylated ligand are present in a known concentration. The SH2-like domain or a subdomain thereof and the phosphorylated ligand are incubated with a substance which is suspected of affecting an SH2-phosphorylated ligand regulatory system. The method is carried out under conditions which permit the formation of the SH2-phosphorylated ligand complex. SH2-phosphorylated ligand complex, free SH2-like domain or subdomains thereof, or non-complexed phosphorylated ligand are assayed. The invention also relates to an isolated SH2-phosphorylated ligand complex; a method of using an isolated SH2-like domain or a subdomain thereof to screen for phosphorylated ligands which are active in an SH2-phosphorylated ligand regulatory system; a method of using an isolated SH2-like domain or a subdomain thereof to regulate the interaction of a signalling protein with a related phosphorylated ligand; and a pharmaceutical composition comprising an isolated SH2-like domain or a subdomain thereof for use as an agonist or antagonist of the interaction of a signalling protein with a related phosphorylated ligand.
CA002054602A 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system Expired - Fee Related CA2054602C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US07/786,057 US5352660A (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
CA002054602A CA2054602C (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
CA002417838A CA2417838A1 (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh-2 phosphorylated ligand regulatory system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/786,057 US5352660A (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
CA002054602A CA2054602C (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002417838A Division CA2417838A1 (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh-2 phosphorylated ligand regulatory system

Publications (2)

Publication Number Publication Date
CA2054602A1 true CA2054602A1 (en) 1993-05-01
CA2054602C CA2054602C (en) 2003-04-22

Family

ID=25674846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002054602A Expired - Fee Related CA2054602C (en) 1991-10-31 1991-10-31 Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Country Status (2)

Country Link
US (1) US5352660A (en)
CA (1) CA2054602C (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1995002057A1 (en) * 1993-07-09 1995-01-19 The Institute Of Cancer Research Protein tyrosine kinase and ligands thereof
WO1995031545A2 (en) * 1994-05-13 1995-11-23 Children's Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein
EP0750630A1 (en) * 1994-03-11 1997-01-02 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
WO1997032020A2 (en) * 1996-02-29 1997-09-04 Mount Sinai Hospital Corporation Shc proteins
EP0804218A1 (en) * 1994-03-17 1997-11-05 National Jewish Center For Immunology And Respiratory Medicine Product and process for regulating signal transduction pathways
WO1998057177A1 (en) * 1997-06-09 1998-12-17 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652576B2 (en) 1990-09-13 1994-09-01 Duke University Expression of G protein coupled receptors in yeast
CA2100860C (en) * 1991-01-18 2003-11-25 Joseph Schlessinger A receptor tyrosine kinase target protein cdna cloning method and hgrb proteins
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6262023B1 (en) 1994-02-01 2001-07-17 The Board Of Trustees Of The Leland Stanford Junior University WD-40 derived peptides and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6423684B1 (en) 1994-02-01 2002-07-23 The Board Of Trustees Of The Leland Stanford Junior University WD-40 derived peptides and uses thereof
US6037134A (en) * 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
DE69532127T2 (en) * 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge INTERACTION FILLING SYSTEMS FOR DETECTING PROTEIN INTERACTIONS
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5786454A (en) * 1994-09-16 1998-07-28 Washington University School Of Medicine Modified SH2 domains
US5744313A (en) * 1994-12-09 1998-04-28 The Regents Of The University Of California Assay employing novel protein domain which binds tyrosine phosphorylated proteins
US5659012A (en) * 1995-03-10 1997-08-19 Whitehead Institute For Biomedical Research Peptide which binds SH2 domains of protein tyrosine phosphatase SH-PTP1
AU711141B2 (en) * 1995-04-07 1999-10-07 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
US6280964B1 (en) * 1995-04-14 2001-08-28 The Regents Of The University Of California Binding sites for phosphotyrosine binding domains
AU6405596A (en) * 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
AU6480796A (en) * 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 6 sh2 domain specific compounds to treat allergic reactions
EP0871648A1 (en) * 1995-09-15 1998-10-21 Merck & Co., Inc. A high throughput assay using fusion proteins
US5776696A (en) * 1995-09-15 1998-07-07 Merck & Co., Inc. High throughput assay using fusion proteins
US5783398A (en) * 1995-09-15 1998-07-21 Merck & Co., Inc. High throughput assay using fusion proteins
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
CA2235756A1 (en) * 1995-10-27 1997-05-01 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
JP2000506007A (en) * 1996-02-23 2000-05-23 アリアド・ファーマシューティカルズ・インコーポレイテッド Cell-based assays
WO1997039326A2 (en) * 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US6207397B1 (en) 1996-04-18 2001-03-27 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5912138A (en) * 1996-07-25 1999-06-15 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US20030036106A1 (en) * 1996-10-28 2003-02-20 Burke Thomas J. Kinase and phosphatase activity measurement using fluorescence polarization
WO1998021585A1 (en) 1996-11-15 1998-05-22 Cornell Research Foundation, Inc. Activated ras interaction assay
ATE271130T1 (en) 1997-02-07 2004-07-15 Univ Princeton MODIFIED PROTEIN KINASES THAT CAN USE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES
US20030096760A1 (en) * 1997-03-10 2003-05-22 Smithklinebeecham Corporation Method of antagonizing the human SRC SH2 domain
WO1998041866A1 (en) * 1997-03-14 1998-09-24 Merck & Co., Inc. A high throughput assay using fusion proteins
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US6440386B1 (en) 1998-07-06 2002-08-27 Immunomedics, Inc. Stabilized radiophosphate-labeled proteins
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
US6610483B1 (en) * 1999-07-23 2003-08-26 Princeton University Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
US6165728A (en) * 1999-11-19 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of NCK-2 expression
EP1377828A4 (en) * 2001-04-10 2006-11-15 Childrens Medical Center Methods of analysis and labeling of protein-protein interactions
US20030166502A1 (en) * 2001-05-10 2003-09-04 Washington University Differential regulation of T cell survival and proliferation
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2005021546A1 (en) * 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP2013537410A (en) 2010-07-23 2013-10-03 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Genome editing using targeted endonucleases and single-stranded nucleic acids
CN117517041B (en) * 2024-01-08 2024-04-02 嘉华药锐生物科技(昆山)有限公司 Method for improving enrichment efficiency of tyrosine phosphorylated peptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100661A (en) * 1988-03-21 1992-03-31 Eye Research Institute Of Retina Foundation Method for regulating cellular signal transducing system

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1995002057A1 (en) * 1993-07-09 1995-01-19 The Institute Of Cancer Research Protein tyrosine kinase and ligands thereof
EP0750630A4 (en) * 1994-03-11 1998-01-07 Ariad Pharma Inc Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
EP0750630A1 (en) * 1994-03-11 1997-01-02 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
EP0804218A4 (en) * 1994-03-17 1997-11-12
EP0804218A1 (en) * 1994-03-17 1997-11-05 National Jewish Center For Immunology And Respiratory Medicine Product and process for regulating signal transduction pathways
US5667981A (en) * 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
WO1995031545A3 (en) * 1994-05-13 1996-08-01 Los Angeles Childrens Hospital Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein
WO1995031545A2 (en) * 1994-05-13 1995-11-23 Children's Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein
WO1997032020A2 (en) * 1996-02-29 1997-09-04 Mount Sinai Hospital Corporation Shc proteins
WO1997032020A3 (en) * 1996-02-29 1997-11-13 Mount Sinai Hospital Corp Shc proteins
US6077686A (en) * 1996-02-29 2000-06-20 Mount Sinai Hospital Corporation Shc proteins
WO1998057177A1 (en) * 1997-06-09 1998-12-17 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents

Also Published As

Publication number Publication date
US5352660A (en) 1994-10-04
CA2054602C (en) 2003-04-22

Similar Documents

Publication Publication Date Title
CA2054602A1 (en) Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
Berk et al. Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and-independent pathways.
Sun Growth stimulation of 3T3 fibroblasts by cystatin
EA199700280A1 (en) PROTEINKINASE C INHIBITORS
IL74303A0 (en) Compositions and test device for determining the presence of leukocytes
AUPP004497A0 (en) Stabilized particles
WO1997011690A3 (en) Inhibitors of regulatory pathways
Gartung et al. Internalization of blocking antibodies against mannose‐6‐phosphate specific receptors.
EP0726908A4 (en) Oncoprotein protein kinase
CA2167048A1 (en) Identification of ligands by selective amplification of cells transfected with receptors
Law et al. Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells.
SE9203118D0 (en) A METHOD OF PREVENTING UNDESIRED BINDING IN SOLID PHASE ASSAYS
TR199800644T2 (en) y-RAR antagonist ligand or alpha-RAR antagonist ligand as an apoptosis inhibitor.
DE69031121T2 (en) INTERFERENCE PREVENTION WITH AFFINITY COLLECTION SCHEMES
KR930007882A (en) Cytotoxic bicyclo [7.3.1] tride-4 sen-2,6diyne compounds and preparation methods thereof
ES8501801A1 (en) Test for esterase activity in a liquid sample.
Santiago et al. Entamoeba histolytica: PKC transduction pathway activation in the trophozoite-fibronectin interaction
CA2094276A1 (en) Antibodies against the urokinase receptor and their use
EP0753147A1 (en) Screening method using the rzr receptor family
Melamed et al. Tyrosine phosphorylation is essential for microfilament assembly in B lymphocytes
Kaplowitz et al. Hepatic glutathione S-transferases: identification by gel filtration and in vitro inhibition by organic anions
WO2002014542A3 (en) Process for detecting serine/threonine kinase activity
GB2248298B (en) Probes,kits and methods for the detection and differentiation of mycobacteria
AU3927989A (en) Two-site confirmatory assay
FR2594831B1 (en) PROLINE DERIVATIVES, THEIR PREPARATION METHOD, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND METHOD FOR INHIBITING THE ANGIOTENSIN-TRANSFORMING ENZYME

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed